Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
An international team of researchers has uncovered evidence of partial resistance to artemisinin derivatives -- the primary treatment for malaria -- in young children with severe malaria.